MICHELLE LYNOTT: Open Payments
NPI 1881887339 · PRESCOTT, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,135 in 81 payments from 16 companies in 2025. Trend: 2023 $2,034 · 2024 $1,583 · 2025 $2,135
Food & beverage: $2,135
| Company | Payments | Amount |
|---|---|---|
| Madrigal Pharmaceuticals | 9 | $507 |
| ABBVIE INC. | 19 | $408 |
| Gilead Sciences, Inc. | 11 | $265 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $236 |
| Janssen Biotech, Inc. | 8 | $153 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $103 |
| Lilly USA, LLC | 3 | $79 |
| Aimmune Therapeutics, Inc. | 4 | $75 |
| Ipsen Biopharmaceuticals, Inc | 3 | $70 |
| Intercept Pharmaceuticals, Inc. | 3 | $61 |
Products named: REZDIFFRA, ENTYVIO, LINZESS, TREMFYA, SKYRIZI, XIFAXAN, OMVOH, ZENPEP.
Industry payments across AZ — which companies pay providers there.
